Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in HER2-negative advanced gastric or GEJ adenocarcinoma
NCT03675737Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Primary completion
- Oct 2022
- Countries
- 33
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03675737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675737.